Northbrook, IL 60062 -- (SBWIRE) -- 01/18/2024 -- Base Editing Market in terms of revenue was estimated to be worth $270 million in 2023 and is poised to reach $549 million by 2028, growing at a CAGR of 15.2% from 2023 to 2028 according to a new report by MarketsandMarkets. Growing interest in gene editing technologies, including base editing, has attracted substantial funding and investment from both public and private sources. This financial support is crucial for research and development efforts, accelerating the commercialization of base editing technologies. However, ethical & safety concerns are the factors restraining market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21238371

Browse in-depth TOC on "Base Editing Market"

311 - Tables
41 - Figures
274 - Pages

The platform segment accounted for the largest share by product & service in the base editing market in 2022.

By product and service, the base editing market has been further categorized as products and services. The service segment is further categorized as gRNA design, cell line engineering, and other services. The product segment is further categorized as platform, kits & reagents, plasmids, and base editing libraries. Platform accounted for the largest share of the global base editing market in 2022. The large share of this segment can primarily be attributed to the factor that it offers integrated solutions that combine various elements required for the editing process, such as the base editor protein, guide RNA, and delivery mechanisms. This integration simplifies the workflow for researchers, as they can obtain a complete solution from a single source rather than assembling individual components.

The DNA base editing type segment is expected to grow at a higher rate during the forecast period 2023-2028.

Based on the type, the global base editing market is segmented into RNA base editing, and DNA base editing. In 2022, DNA base editing accounted for the largest share of the base editing market and the segment is expected to grow at a higher rate during the forecast period. The prominence of this segment is mainly attributed to the factor that once a base is edited in the DNA, the change is more stable over time compared to RNA-based editing. RNA is typically transient in cells, and the edits made to RNA may not persist as long as those made to DNA.

The pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the end user segment in the base editing market in 2022.

Based on end users, the base editing market has been segmented into pharmaceutical & biotechnology companies, academic research institutes, and contract research organizations. In 2022, the pharmaceutical & biotechnology segment accounted for the largest share of the base editing market. One of the major factors driving the growth of this segment is that base editing enables precise modifications at the DNA or RNA level, allowing pharmaceutical and biotech companies to develop targeted therapies for specific genetic diseases. This aligns with the industry's shift toward precision medicine, where treatments are tailored to the individual genetic makeup of patients.

The North American region catered for the largest share of the base editing market in 2022.

The base editing market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East and Africa (MEA). The availability of funding, both public and private, plays a crucial role in the development and commercialization of advanced technologies. North America has a well-established infrastructure for funding research and development initiatives, providing financial support to companies working on base editing technologies.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=21238371

Base Editing Market Dynamics:

Drivers:

1. Increasing government funding and growing focus on genomic studies
2. Increased applications of genomic research in pharmaceuticals
3. Rising prevalence of rare diseases
4. Increased precision, better safety, and reduced off-target effects

Restraints:

1. Ethical and safety concerns

Opportunities:

1. Increasing pipeline of gene therapy products and regulatory approvals

Challenge:

1. Lack of expertise to develop base editors with higher specificity

Key Market Players of Base Editing Industry:

Key players in the base editing market include Danaher Corporation (US), Merck KGaA (Germany), Revvity (US), Maravai LifeSciences (US), GenScript (China), Beam Therapeutics (US), Intellia Therapeutics, Inc. (US), Cellectis (France), ElevateBio (US), Creative Biogene (US), Bio Palette Co., Ltd (Japan), Addgene (US), Synthego (US), Edigene, Inc. (China), Shape TX (US), Pairwise (US), ProQR Therapeutics (Netherlands), QI- Biodesign (China), KromaTiD, Inc. (US), and GenKOre. (South Korea).

The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=21238371

Base Editing Market Recent Developments:

- In May 2023, Revvity entered into a license agreement with AstraZeneca for the technology underlying its Pin-point base editing system, a next-generation modular gene editing platform with a strong safety profile to support their creation of cell therapies for the treatment of cancer and immune-mediated diseases.

- In July 2022, Beam Therapeutics entered a collaboration with Verve Therapeutics. Beam Tx granted Verve Tx a license toward an additional liver-mediated cardiovascular disease target.

- In February 2022, Intellia Therapeutics acquired Rewrite Therapeutics; a private biotechnology company focused on advancing novel DNA writing technologies. This acquisition has expanded Intellia's industry-leading genome editing toolbox by adding a platform that is highly complementary to its existing CRISPR/Cas9 and base editing technologies.

About MarketsandMarkets™:

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com